CG Oncology, Inc. experienced a notable increase in its stock price, reflecting positive investor sentiment.
CG Oncology, Inc. Common stock saw a rise of 3.66% in its stock price yesterday, closing at CA$69.61. This uptick comes amid significant clinical developments and financial stability within the company.
Investor takeaway: Investors are optimistic about CG Oncology's future prospects, particularly with upcoming clinical trial data and a solid cash position.
Advertisement
CG Oncology, Inc. Common stock
CGON.US
CGON.US
CG Oncology, Inc. Common stock
WealthAwesomeMarket cap
$6.17B
52W high
$80.97
52W low
$35.80
1W change
-11.04%
Beta
0.24
Analyst Price Targets
Based on 10 analysts covering CGON · as of Sep 17, 2026
Wall Street analysts forecast CGON stock price to rise 30.8% over the next 12 months.
Consensus
Buy4.40 / 5.00
Avg. Target
C$91.08
+30.8% Upside
Current Price
C$69.61
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CGON's historical volatility
30-Day Vol
46.7%
Annualized
90-Day Vol
49.0%
Annualized
Trend (90d)
-4.5%
Annualized drift
90d Mean
C$68.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$69.24 | C$58.94 – C$81.33 |
| 60 trading days | C$68.87 | C$54.85 – C$86.47 |
| 90 trading days | C$68.50 | C$51.83 – C$90.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
CG Oncology's stock price increased by 3.66%
The rise in stock price reflects growing investor confidence in CG Oncology's clinical advancements and financial health.
Bull case
The company has about $1.0 billion in cash reserves, which gives it a strong buffer for ongoing operations and development. This solid financial position sets CG Oncology up well for future milestones in its clinical pipeline.
Bear case
Despite the positive movement, the lack of immediate news or catalysts could lead to volatility. Additionally, the company's reliance on clinical trial outcomes carries inherent risks.
Strong Financial Position
Advertisement
CG Oncology's market cap is around $6.17 billion, backed by a robust cash position that ensures funding for operations through 2029. This financial stability is crucial as the company navigates the complexities of clinical trials and regulatory approvals.
Upcoming Clinical Milestones
Investors are particularly focused on the anticipated topline data from the PIVOT-006 Phase 3 trial, which evaluates cretostimogene in treating intermediate-risk non-muscle invasive bladder cancer. Positive results could significantly enhance the company's market position and drive further stock appreciation.
Market Reaction
The increase in CG Oncology's stock price reflects a positive market reaction to the company's ongoing clinical advancements and the publication of significant study results in reputable medical journals. As the company continues to make strides in its clinical programs, investor sentiment remains cautiously optimistic.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
